Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study

BACKGROUND: Dermatomyositis (DM) is a rare autoimmune disease characterized by skin involvement, with or without proximal muscle weakness. Recently, following the ProDERM study, intravenous immunoglobulin (IVIg) was approved for treatment of DM. Until ProDERM evidence from large, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Werth, Victoria P., Aggarwal, Rohit, Charles-Schoeman, Christina, Schessl, Joachim, Levine, Todd, Kopasz, Norbert, Worm, Margitta, Bata-Csörgő, Zsuzsanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550512/
https://www.ncbi.nlm.nih.gov/pubmed/37799613
http://dx.doi.org/10.1016/j.eclinm.2023.102234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550512/
https://www.ncbi.nlm.nih.gov/pubmed/37799613
http://dx.doi.org/10.1016/j.eclinm.2023.102234

Ejemplares similares